Table 1 Best of 2025 in prostate cancer and prostatic diseases.
From: Best of 2025 in prostate cancer and prostatic diseases
First Author | Topic | Key Findings |
|---|---|---|
Amiri A1 | Statin, genetics and PCa risk | Statin use is not associated with PCa risk or HG PCa risk, even when adjusting for genetic susceptibility |
Garcia Becerra C2 | Biparametric MRI | bpMRI and mpMRI have overlapping accuracy, with bpMRI presenting better ability to reduce false positives. |
Zhao Y3 | Machine learning in MRI | Machine learning MRI present and AUC of 0,96 with 92% of sensitivity and 90% of specificity. |
Klotz L 4 | Prognostic role of negative MRI in AS | MRI invisible cancers demonstrated dramatically reduced rates of progression, and no patient required intervention. Targeted biopsies may be sufficient in these patients. |
Gebrael G5 | Genetic testing in mHSPCa | TP53 (HR: 1,71;p < 0,05), RB1(HR: 2,32;p < 0,05), PTEN(HR: 1,74; p < 0,05), and BRCA2(HR: 2,64; p < 0,05) alterations are all associated with significantly shorter progression-free survival. |
Francolini G 6 | SBRT after progression in CRPC treated with abiraterone | SBRT after progression may be a viable and feasible option for omCRPC after progression if compared to second-line systemic therapy. |
Zheng R7 | NLM and PCa communication | Integrating natural language processors in clinical consultations may improve shared decision-making in PCa communication. |
Masterson J8 | Life expectancy and treatment preferences across racial and ethnic groups | Life expectancy is interpreted differently across cultures, with a great impact on PCa decision-making. |
Elmansy H9 | Moses holmium vs thulium enucleation | M-HoLep presents similar functional outcomes vs ThuLep. Surgical efficiency and complications favor M-HoLep. Single-surgeon design warrants caution in interpretation. |
Manfredi C10 | Rezum vs ThuLep | ThuLep is superior to Rezum in terms of IPSS and Qmax but not clinically different. Rezum presents a better sexual safety profile. |
